Download PDF
CC BY-NC-ND 4.0 · Journal of Diabetes and Endocrine Practice 2022; 05(02): 080-082
DOI: 10.1055/s-0042-1755440
Case Report

Euglycemic Diabetic Ketoacidosis after the Initiation of Treatment in a Patient with New-Onset Type 2 Diabetes Mellitus

Omar Alhaj
1   Internal Medicine Residency Program, Department of Academic Affairs, Tawam Hospital, Al Ain, United Arab Emirates
,
Bachar Afandi
2   Department of Medicine, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates
3   Endocrine Division, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates
4   Endocrine Division, Tawam Hospital, Al Ain, United Arab Emirates
› Author Affiliations Funding None.
› Further Information
Also available at
   Permissions and Reprints

Abstract

We report the onset of euglycemic diabetic ketoacidosis (EDKA) in a 20-year-old male patient with new-onset type 2 diabetes mellitus (T2DM) 5 days after the initiation of diet restriction and the combination of SGLT2 (sodium–glucose co-transporter 2) inhibitors, glucagon-like peptide 1 receptor agonists, and metformin. The use of SGLT2 inhibitors in symptomatic patients with new-onset T2DM along with the extreme reduction in carbohydrate intake might trigger the onset of EDKA. Judicious, stepwise use of available diabetes therapies and strict monitoring can reduce the risk of this complication.

Keywords

SGLT2 inhibitors - new-onset type 2 diabetes - hyperglycemia - euglycemic - DKA - ketoacidosis


Publication History

Article published online:
15 September 2022

© 2022. Gulf Association of Endocrinology and Diabetes (GAED). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Rawla P, Vellipuram AR, Bandaru SS, Pradeep Raj J. Euglycemic diabetic ketoacidosis: a diagnostic and therapeutic dilemma. Endocrinol Diabetes Metab Case Rep 2017; 2017: 17-0081
    PubMedSearch in Google Scholar
  • 2 Joseph F, Anderson L, Goenka N, Vora J. Starvation-induced true diabetic euglycemic ketoacidosis in severe depression. J Gen Intern Med 2009; 24 (01) 129-131
    CrossrefPubMedSearch in Google Scholar
  • 3 Prater J, Chaiban J. Euglycemic diabetic ketoacidosis with acute pancreatitis in a patient not known to have diabetes. Endocr Pract 2015; 1: e88-e91
    Search in Google Scholar
  • 4 Chico M, Levine SN, Lewis DF. Normoglycemic diabetic ketoacidosis in pregnancy. J Perinatol 2008; 28 (04) 310-312
    CrossrefPubMedSearch in Google Scholar
  • 5 Rosenstock J, Ferrannini E, Ketoacidosis ED. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 2015; 38 (09) 1638-1642
    CrossrefPubMedSearch in Google Scholar
  • 6 Plewa MC, Bryant M, King-Thiele R. Euglycemic Diabetic Ketoacidosis. [Updated January 24, 2022]. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2022. Accessed July 22, 2022 at: https://www.ncbi.nlm.nih.gov/books/NBK554570/
  • 7 Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 2015; 38 (09) 1687-1693
    CrossrefPubMedSearch in Google Scholar
  • 8 Modi A, Agrawal A, Morgan F. Euglycemic diabetic ketoacidosis: a review. Curr Diabetes Rev 2017; 13 (03) 315-321
    CrossrefPubMedSearch in Google Scholar
  • 9 Yu X, Zhang S, Zhang L. Newer perspectives of mechanisms for euglycemic diabetic ketoacidosis. Int J Endocrinol 2018; 2018: 7074868
    PubMedSearch in Google Scholar
  • 10 Goldenberg RM, Berard LD, Cheng AYY. et al. SGLT2 Inhibitor-associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis. Clin Ther 2016; 38 (12) 2654.e1-2664.e1
    CrossrefPubMedSearch in Google Scholar
  • 11 Draznin B, Aroda VR, Bakris G. et al; American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes-2022. Diabetes Care 2022; 45 (Suppl. 01) S125-S143
    PubMedSearch in Google Scholar
  • 12 Garber AJ, Handelsman Y, Grunberger G. et al. Consensus statement by the american association of clinical endocrinologists and american college of endocrinology on the comprehensive type 2 diabetes management algorithm – 2020 executive summary. Endocr Pract 2020; 26 (01) 107-139
    CrossrefPubMedSearch in Google Scholar
  • 13 Davies MJ, D'Alessio DA, Fradkin J. et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018; 41 (12) 2669-2701
    Search in Google Scholar
  • 14 American Diabetes Association. 13. Children and adolescents: Standards of Medical Care in Diabetes-2020 . Diabetes Care 2020; 43 (Suppl. 01) S163-S182
    CrossrefPubMedSearch in Google Scholar
  • 15 LeRoith D. Beta-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities. Am J Med 2002; 113 (Suppl 6A): 3S-11S
    CrossrefPubMedSearch in Google Scholar
  • 16 Dubois M, Vacher P, Roger B. et al. Glucotoxicity inhibits late steps of insulin exocytosis. Endocrinology 2007; 148 (04) 1605-1614
    CrossrefPubMedSearch in Google Scholar
  • 17 Blau JE, Tella SH, Taylor SI, Rother KI. Ketoacidosis associated with SGLT2 inhibitor treatment: analysis of FAERS data. Diabetes Metab Res Rev 2017; 33 (08) 33
    Search in Google Scholar
  • 18 Fralick M, Schneeweiss S, Patorno E. Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N Engl J Med 2017; 376 (23) 2300-2302
    CrossrefPubMedSearch in Google Scholar